Protara Therapeutics, Inc. TARA
Protara Therapeutics, Inc. (Nasdaq: TARA) is an oncology drug developer. Its lead program, TARA-002 (intravesical), ADVANCED-2, is in Phase 2 for BCG-unresponsive / BCG-naive high-grade NMIBC with CIS. Its next catalyst on record is IV Choline Chloride (THRIVE-3): Interim results from dose-confirmation portion (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IV Choline Chloride (THRIVE-3) — Interim results from dose-confirmation portion (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TARA-002 ADVANCED-2 (Cohort B registrational; Cohort A BCG-naive enrolled) | Non-muscle invasive bladder cancer (CIS) | cell therapy | Phase 2 |
| TARA-002 STARBORN-1 (pivotal Phase 2) | Macrocystic and mixed-cystic lymphatic malformations | cell therapy | Phase 2 |
| IV Choline Chloride THRIVE-3 (seamless Phase 2b/3) | Choline source for patients on long-term parenteral support | small molecule | Phase 2 |
| TARA-002 ADVANCED-3 (redesigned exploratory multi-cohort) | BCG-naive/exposed CIS and papillary NMIBC | cell therapy | Phase 2 |
Recent results and decisions
- Feb 23, 2026positive BCG-Unresponsive interim: CR 68.2% (15/22) at 6 months, 33.3% (5/15) at 12 months, 65.7% (23/35) at any time; no Grade 3+ treatment-related AEs.
The CR rate was 68.2% (15 of 22) at six months and 33.3% (5 of 15) at 12 months
Filing - Dec 3, 2025positive Updated interim in BCG-Naive NMIBC: CR at any time 72% (21/29), 69% (18/26) at 6 months, 50% (7/14) at 12 months; no Grade 3+ treatment-related AEs.
The CR rate at any time was 72% (21/29).
Filing - Dec 3, 2025n/a FDA provided written feedback supporting a controlled registrational design in BCG-Naive patients, with CR at month 6 as primary endpoint and chemotherapy an acceptable comparator.
The FDA has provided written feedback supporting a registrational design for a controlled trial in BCG-Naïve patients
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.